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Abstract
Guillain-Barre ´ syndrome (GBS) is a monophasic immune neuropathic disorder in which a significant proportion of patients
have incomplete recovery. The patients with incomplete recovery almost always have some degree of failure of axon
regeneration and target reinnervation. Anti-ganglioside antibodies (Abs) are the most commonly recognized autoimmune
markers in all forms of GBS and specific Abs are associated with the slow/poor recovery. We recently demonstrated that
specific anti-ganglioside Abs inhibit axonal regeneration and nerve repair in preclinical models by activation of small GTPase
RhoA and its downstream effectors. The objective of this study was to determine whether erythropoietin (EPO), a pleiotropic
cytokine with neuroprotective and neurotrophic properties, enhances nerve regeneration in preclinical cell culture and
animal models of autoimmune neuropathy/nerve repair generated with monoclonal and patient derived Abs. Primary
neuronal cultures and a standardized sciatic crush nerve model were used to assess the efficacy of EPO in reversing
inhibitory effects of anti-ganglioside Abs on nerve repair. We found that EPO completely reversed the inhibitory effects of
anti-ganglioside Abs on axon regeneration in cell culture models and significantly improved nerve regeneration/repair in an
animal model. Moreover, EPO-induced proregenerative effects in nerve cells are through EPO receptors and Janus kinase 2/
Signal transducer and activator of transcription 5 pathway and not via early direct modulation of small GTPase RhoA. These
preclinical studies indicate that EPO is a viable candidate drug to develop further for neuroprotection and enhancing nerve
repair in patients with GBS.
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Introduction
Anti-ganglioside antibodies (Abs) are the most commonly
recognized autoimmune markers in all forms of Guillain-Barre ´
syndrome (GBS) [1,2]. Association between axonal variants of
GBS and specific anti-ganglioside Abs is now widely accepted
[1,3]. The full spectrum of anti-ganglioside Ab-mediated patho-
biologic effects and associated mechanisms remains to be defined.
Several studies suggest that GBS patients with IgG and/or IgM
anti-ganglioside Abs directed against GM1 or GD1a recover more
slowly and have poorer prognosis [4–14]. Anti-ganglioside Abs
induce impairment of nerve repair is supported by our studies
showing that monoclonal and patient-derived anti-ganglioside Abs
inhibit axon regeneration and nerve repair after injury in an
animal model [15,16]. Further, we have established primary
neuronal culture models in which anti-ganglioside Abs inhibit
neurite/axon outgrowth [17]. Our cell culture studies establish
that anti-ganglioside Abs induce inhibition via activation of small
GTPase RhoA and its key downstream effector Rho kinase [17].
These models are not only critical to study the mechanisms
underlying failure of axon regeneration in GBS cases with anti-
ganglioside Abs and slow/poor recovery but they also provide an
opportunity to examine therapeutic interventions to enhance axon
regeneration in preclinical studies.
Erythropoietin (EPO), ,34-kD glycoprotein, is a pleiotropic
cytokine originally identified for it role in erythropoiesis [18]. It
also has remarkable protective activity in preclinical models of
different tissue injury. Notably, EPO has been shown to be
neuroprotective in animal models of stroke, spinal cord and
peripheral nerve injury, and experimental autoimmune enceph-
alomyelitis [19–21]. EPO readily penetrates the blood-brain
barrier (BBB) [19] and recent phase II studies showed that
peripherally administered EPO is beneficial in stroke and multiple
sclerosis patients [22,23]. Some in vitro and in vivo studies suggest
that EPO may promote neurite/axon regeneration in the central
as well as the peripheral nervous system [24–27].
Since a significant proportion of cases with GBS are left with
residual damage despite use of current immunomodulatory
therapies, i.e., intravenous immunoglobulins and plasma ex-
change, the need to develop therapies to protect the neural
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axonal regeneration and target reinnervation in the recovery
period is increasingly realized. In view of this need, we examined
the proregenerative effects of recombinant human EPO in
preclinical models of inhibited axon regeneration induced with
autoimmune Abs relevant to GBS. We found that EPO can
significantly attenuate the anti-ganglioside Abs mediated inhibition
of axon regeneration/nerve repair, and cell culture studies show
that EPO induced proregenerative effect is through EPO receptor
(EPOR) and sequentially activating Janus kinase 2 (JAK2)/Signal
transducer and activator of transcription 5 (STAT5) pathway.
Results
EPO enhances neurite outgrowth of normal primary
sensory and motor neurons
To show proregenerative effects of EPO, we examined whether
EPO enhances neurite outgrowth of primary dorsal root ganglion
(DRG) and spinal motor neuron cultures. Motor and sensory
neurons account for ,80% and ,50% of the total cell population
in the primary spinal motor and DRG neuronal cultures,
respectively. EPO (100 pM) significantly enhanced neurite
outgrowth of both primary sensory (< 60%) (Fig. 1A–C) and
motor neurons (< 70%) (Fig. 1D).
EPO reverses anti-ganglioside Ab-mediated inhibition of
neurite outgrowth
We have previously shown that anti-ganglioside Abs inhibit
neurite outgrowth in primary neuronal cultures [17], therefore, we
examined whether EPO reverses this inhibitory effects of anti-
ganglioside Abs. For these studies we used anti-GD1a/GT1b
IgG2b (GD1a/GT1b–2b) monoclonal antibody (mAb), a proto-
typic antibody which has been extensively characterized for its
inhibitory effects on axon/neurite outgrowth in animal and cell
culture studies [15,17]. Consistent with our previous results [17],
the current studies showed that GD1a/GT1b–2b mAb signifi-
cantly inhibited neurite outgrowth of both sensory (embryonic,
postnatal rat and adult mouse DRG) and motor (embryonic rat)
neurons in overnight cultures by 30–50% compared to control
mAb-treated cultures. EPO completely reversed the GD1a/
GT1b–2b mAb-mediated inhibition of neurite outgrowth in
sensory and motor neuron cultures (Fig. 2). EPO dose-responsive-
ness was examined in primary embryonic rat DRG cultures
treated with GD1a/GT1b–2b mAb, and we found dose-
Figure 1. EPO enhances neurite outgrowth in control primary neurons. Primary DRG neurons without EPO treatment (A) and with EPO
treatment (B). Scale bar, 20 mm. Quantified data showing that EPO treated DRG (n=300–500 neurons) (C) or spinal motor neurons (MN) (n=300–500
neurons) (D) have significantly longer neurites. * p,0.05.
doi:10.1371/journal.pone.0027067.g001
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peaking at 10–100 pM (Fig. 2D). Since anti-ganglioside Abs and
EPO induced similar effects on sensory and motor neuron
cultures, remaining studies were performed on DRG cultures
because of higher cell yields and easier preparation techniques.
EPO reverses GBS sera’s inhibitory effect on neurite
outgrowth
Our previous studies shown that IgG anti-ganglioside Abs
against GD1a or GM1 present in GBS patient sera can
significantly inhibit the neurite outgrowth of primary neuronal
cells and the regeneration of injured axons in animals [16,17]. In
the current study, we examined whether EPO reverses the
inhibitory effects of GBS patient sera on neurite outgrowth in
primary neuronal cultures. GBS sera with high titers (1:10,000 to
1:20,000) of IgG anti-GD1a and/or GM1 Abs, collected from
patients with acute motor axonal neuropathy (AMAN) during the
acute phase of the disease, were used in the cell culture studies.
The clinical, electrophysiological and serological features of these
patients were published previously [28]. We found that IgG
fractions obtained from GBS sera induced significant inhibition of
neurite outgrowth in DRG neurons (Fig. 3A) compared to IgG
fractions from control sera (Fig. 3B). This result is consistent with
our previous findings showing that GBS sera induce inhibition of
axon regeneration in an animal model [16]. Our results show that
the treatment with EPO almost completely reversed neurite
outgrowth inhibition induced by IgG fractions obtained from GBS
sera (Fig. 3C). These studies indicate that EPO reverses not only
the anti ganglioside mAb-mediated outgrowth inhibition, but also
the inhibition induced with patient Abs.
EPO-induced neurite outgrowth is mediated by JAK2/
STAT5 pathway through EPOR
This set of studies evaluated the role of EPOR and JAK2/
STAT5 pathway in EPO-mediated proregenerative effects in our
cell culture models, because EPOR is expressed on motor and
sensory DRG neurons [29–32] and JAK2/STAT5 are known to
be involved in EPOR mediated intracellular signaling [33,34]. In
our initial immunocytochemical studies, we confirmed that EPOR
is expressed by primary neurons in culture (data not shown). To
test the role of EPOR in the enhancement of neurite outgrowth in
our cell culture models, we applied soluble EPOR or anti-EPOR
blocking antibody [34] in DRG cultures. Our results show that
soluble EPOR competitively abolishes EPO’s neuroregenerative
effect (Fig. 4A). Additionally, EPO’s proregenerative effects were
almost completely abolished with an anti-EPOR blocking
antibody in this model (Fig. 4B).
Western blotting studies were performed to assess the role of
JAK2/STAT5 pathway in our cell culture model. We found that
EPO induced tyrosine-phosphorylation of several proteins in
primary DRG cells, some of which migrated to molecular weights
corresponding to JAK2, STAT5, and EPOR (Fig. 4C). Phosphor-
ylation of STAT5 in DRG cultures was confirmed with a specific
antibody (Fig. 4D). Functional studies showed that JAK2 inhibitor,
AG490, blocked EPO-mediated enhancement of neurite out-
growth of DRG neurons (Fig. 4E), and this blockage by AG490 is
dose-dependent (data not shown).
EPO does not modulate activation of small GTPases
RhoA, Rac1 and Cdc42
We previously reported that specific anti-ganglioside Abs induce
inhibition of neurite outgrowth through the activation of small
Figure 2. EPO reverses GD1a/GT1b–2b mAb-mediated inhibition of neurite outgrowth in primary neuronal cultures. (A) Primary DRG
neurons extend long neurites under control conditions. (B) DRG neurons treated with GD1a/GT1b–2b mAb have shorter neurites. (C) EPO reverses
Ab-mediated inhibition of neurite outgrowth. Scale bar, 20 mm. (D) EPO induces a dose-responsive reversal of Ab-mediated inhibition of neurite
outgrowth in embryonic rat DRG neurons (ER DRG). Quantified data showing that EPO (100 pM) reverses Ab-mediated inhibition of neurite
outgrowth in adult mouse DRG (AM DRG), * p,0.05 (E), and spinal motor neurons (MN), * p,0.01 (F).
doi:10.1371/journal.pone.0027067.g002
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whether EPO modulates the activation of small GTPases (RhoA,
Rac1, and Cdc42), involved in the regulation of growth cone
extension [35–39], in our DRG cultures. We found that EPO did
not alter the activation of RhoA, Rac1 and Cdc42, in the presence
or absence of anti-ganglioside Abs (Fig. 5A–C).
EPO enhances repair in an animal model of anti-
ganglioside Ab-mediated inhibition of axon regeneration
We have established a standardized sciatic nerve crush model in
which anti-ganglioside Abs (mAbs and GBS IgG fractions) inhibit
axon regeneration [15,16]. We next investigated whether EPO
can improve axon regeneration in this animal model. These
studies were limited to GD1a/GT1b–2b mAb because sufficient
quantities of human sera were not available to conduct animal
studies. For these studies, age and gender matched mice
underwent standardized sciatic nerve crush and were evenly
distributed into the following 4 treatment groups: 1) GD1a/
GT1b–2b Ab + EPO; 2) GD1a/GT1b–2b Ab + vehicle; 3)
Control Ab + EPO; and 4) Control Ab + vehicle. Mice were
administrated GD1a/GT1b–2b mAb or control Abs on day 3
after the nerve crush by intraperitoneal route. EPO or vehicle
control was administered subcutaneously to animals 5 days/week
for 30 days after the nerve crush. Previously validated outcome
measures included axon regeneration assessed with morphometry
of sciatic and tibial nerves, and target reinnervation assessed by
sciatic nerve conductions and ex vivo magnetic resonance imaging
(MRI) of the calf muscles [15,16,40].
The efficacy of EPO in mice was confirmed by monitoring RBC
counts in GD1a/GT1b–2b mAb+EPO (Ab+EPO) -treated and
GD1a/GT1b–2b mAb+ vehicle (Ab+vehicle) groups. Our results
show that Ab+EPO -treated group had significant increase in RBC
counts compared to Ab+vehicle-treated animals (data not shown).
Morphological studies showed that EPO treatment increased
the number of myelinated regenerating axons both at sciatic and
tibial nerve levels in Ab+EPO-treated group compared to
Ab+vehicle-treated animals (Fig. 6). Morphometry showed that
at sciatic level there were 16376428 myelinated fibers (MFs) in
Ab+EPO-treated group compared to 13736280 MFs in
Ab+vehicle-treated animals (Fig. 6E); this difference showed a
trend towards significance (p=0.06). At tibial level there were
164633 MFs in Ab+EPO-treated group compared to 90612
MFs in Ab+vehicle-treated animals (Fig. 6F); this difference was
highly statistically significant (p=0.001). The observation that
Ab+EPO group had significant difference at tibial (distal branch)
but only trend towards significance at sciatic level (proximal
nerve) is consistent with the injury paradigm, i.e., more
regenerative fibers close to the crush site reach sciatic level than
the distal tibial level. Our previous study had shown that more
profound inhibitory effect by anti-ganglioside Abs can be found at
tibial nerve compared to the sciatic nerve level [15]. The results
reflect either more regenerating fibers and/or faster rate of
regeneration in the Ab+EPO group manifesting as more robust
growth at tibial/distal level. Overall, our study indicates that
EPO enhances nerve repair in this model of antibody-mediated
inhibition of axon regeneration.
Figure 3. EPO reverses GBS patient IgG-mediated inhibition of neurite outgrowth in primary neuronal cultures. Photomicrographs
showing that GBS IgG fractions induce inhibition of neurite outgrowth in DRG cultures (A), this is reversed by EPO (B). Scale bar, 20 mm. (C)
Quantitative data showing that EPO reversed inhibition induced by seven GBS patients derived IgG fractions containing anti-ganglioside Abs.
* p,0.05.
doi:10.1371/journal.pone.0027067.g003
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conductions and MRI volumetrics of calf muscle in this animal
model. Electrical studies showed that significantly higher propor-
tion of the Ab+EPO-treated animals (80%) had compound muscle
action potential (CMAP) responses at day 26 after the crush
compared to Ab+vehicle-treated group (44%). Quantitative data
Figure 4. The neurotrophic effects of EPO on primary DRG neurons are mediated via EPOR. Neurotrophic effects induced by EPO are
abolished by co-incubation with soluble EPOR (10 mg/ml; sEpoR) (A), and also significantly inhibited by anti-EPOR blocking Abs (5 mg/ml) (B). (C) EPO
induces tyrosine-phosphorylation of several proteins in primary DRG cultures and protein migration corresponding to JAK2, STAT5, and EPOR. (D)
EPO induces phosphorylation of STAT5 in DRG cultures. (E) JAK2 inhibitor (AG490; 25 mM) itself did not affect neurite outgrowth in DRG cultures,
however, it did prevent enhancement of EPO-induced neurite outgrowth of DRG neurons. Control (Ctrl) = Vehicle {1X PBS for EPO; DMSO (0.0005%)
for AG490} + medium. * p,0.01.
doi:10.1371/journal.pone.0027067.g004
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treated group (0.2260.02 mV at day 26; 0.3760.03 mV at day
30) compared to Ab+vehicle-treated (0.0860.01 mV at day 26;
0.1860.02 mV at day 30) animals on days 26 and 30 after the
crush (Fig. 7C). MRI volumetric measurements of total calf
musculature at the termination of study showed significantly lower
total muscle volume in Ab+vehicle-treated group (180612 mm
3)
compared to Ab+EPO-treated animals (22266m m
3) (Fig. 7F).
Both measures showed that EPO significantly enhanced muscle/
target reinnervation.
We also examined the effects of EPO on nerve regeneration in
animals treated with control (unrelated) antibody. We found that
at sciatic and tibial levels there were ,12% more MFs in Control
Ab + EPO -treated group compared to Control Ab+vehicle-
treated animals; this difference did not reach statistical significance
(p=0.07 at sciatic level; p=0.06 at tibial level).
Discussion
Our studies show that systemic administration of EPO enhances
axon regeneration in clinically relevant cell culture and animal
models of nerve repair produced with experimental and patient
autoantibodies directed against gangliosides. The beneficial effects
were observed both on nerve regeneration and target reinnerva-
tion in an animal model as assessed by morphological and
functional measures. EPO is FDA-approved and one of the earliest
recombinant proteins in clinical use as a drug. These preclinical
studies demonstrating EPO-mediated neurotrophism and exten-
sive past experience with this medication make it a valuable
candidate to develop further as a proregenerative therapy in GBS.
The current study focused on antibody-mediated models
because of the prevalence of these immune effectors in patients
with GBS. The presence of anti-GM1 and -GD1a Abs is strongly
associated with axonal forms of GBS, but these Abs (particularly
anti-GM1 Abs) have been reported in up to 20% cases with
demyelinating form of GBS (reviewed in [41]). The relevance of
these Abs to induction of demyelinating forms of GBS is not clear,
however, these Abs have been associated with poor recovery in
demyelinating forms of GBS [4–6,9–13], and we have shown that
GBS patient derived anti-GM1Abs inhibit axon regeneration in an
animal model [16]. Further, the single most important factor
relevant to prognosis in all forms of GBS (including demyelinating
forms) is the extent of axonal injury [42–44]. Therefore, we believe
that the implications of these findings are not restricted to axonal
forms of GBS but that they also extend to demyelinating variants
of the disease. Moreover, Mausberg et al. (submitted simulta-
neously along with this manuscript) show EPO’s efficacy in
experimental autoimmune neuritis (EAN) [42,45–49], a T-cell
orchestrated animal model of acute inflammatory demyelinating
polyneuropathy.
The signaling studies indicate that EPO modulates the growth
state of the neurons in cultures without specifically reversing the
inhibitory signaling induced by anti-ganglioside Abs at the time
points examined. This is supported by results showing that EPO’s
proregenerative effects in primary DRG cultures were mediated
via the activation of EPOR and its downstream signaling cascade
involving JAK2/STAT5. It has been shown that binding of EPO
to EPOR promotes the phosphorylation of JAK2, the phosphor-
ylated receptor sequentially activates several signal transduction
proteins, including STAT5. The activated STAT protein then
binds to the promoters of specific genes in the nucleus and initiates
transcription of those genes [34,50–52]. Recent studies show that
activation of STAT5 is essential for the neurotrophic effects of
EPO on neurite outgrowth [34,53], which is consistent with our
Figure 5. EPO does not modulate the activation of RhoA, Rac1
and Cdc42 in primary DRG cultures. (A) Anti-ganglioside Abs
(GD1a/GT1b–2b; Ab) induced significant RhoA activation; co-incubation
with EPO did not alter the anti-ganglioside Ab-mediated activation of
RhoA. EPO did not induce RhoA activation compared to control. EPO
did not modulate the activation of Rac1 (B) or Cdc42 (C) in the presence
of control or anti-ganglioside Abs. * p,0.001.
doi:10.1371/journal.pone.0027067.g005
EPO and Nerve Repair
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e27067results. The exact signaling cascade downstream of JAK/STAT,
which promotes neurite outgrowth, is not completely character-
ized but some studies have suggested that PI3K/Akt pathway is
partially involved in EPO induced neuroprotective and neuor-
egenerative responses [24,53]. We have previously shown that
anti-ganglioside antibody-mediated activation of small GTPase
RhoA is an early signaling event (within 30 minutes) that induces
inhibition of neurite outgrowth [17]. However, EPO did not
directly alter the anti-ganglioside antibody-mediated early activa-
tion of small GTPases RhoA at the time points examined (up to
30 minutes) indicating that modulation of small GTPases (RhoA,
Rac1, and Cdc42) is not an early signaling event underlying
proregenerative effects of EPO in DRG neuronal cultures. Since
small GTPases RhoA, Rac1, and Cdc42 are considered critical
and essential mediators of growth cone extension in neurons [35–
39], it would not be surprising if these signaling molecules were
indirectly affected later in EPO-treated cultures as our phenotypic
studies typically assess the neurite length after overnight treatment
with Abs and/or EPO. Alternatively, EPO could indirectly
modulate the downstream effectors of RhoA. These signaling
issues are beyond the scope of the current study.
The assertion that EPO modulates the growth state of the
neuron in these preclinical studies is also supported by our animal
model showing that animals treated with control Ab and EPO had
increased numbers of regenerating fibers at both sciatic and tibial
levels compared to the group treated with control Ab and vehicle
Figure 6. EPO enhances the number of regenerating myelinated nerve fibers (MF) in animal model. Light (A, B; scale bar, 10 mm) and
electron (C, D; scale bar, 5 mm) micrographs of tibial nerve sections. Few regenerating myelinated axons (asterisks) are seen in GD1a/GT1b–2b
mAb+vehicle (Ab+vehicle)-treated animals (A, C) compared to GD1a/GT1b–2b mAb+EPO (Ab+EPO)-treated animals (B, D), which have many more
regenerating fibers. Quantified data show increased numbers of regenerating MF at both sciatic nerve (SN) (E) and tibial nerve (TN) (F) levels in
Ab+EPO-treated group compared to Ab+vehicle-treated animals, EPO’s proregenerative effect reached significance at tibial nerve level. * p,0.01.
doi:10.1371/journal.pone.0027067.g006
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Representative CMAP recordings from GD1a/GT1b–2b mAb+vehicle (Ab+vehicle)-treated animals (A) and GD1a/GT1b–2b mAb+EPO (Ab+EPO)-
treated group (B). (C) Quantified data showing significantly increase CMAP amplitudes in Ab+EPO-treated group compared to Ab+vehicle-treated
animals on days 26 and 30 after the nerve crush. MRI 3D reconstructions of calf muscles in Ab+vehicle-treated animals (D) and Ab+EPO-treated group
(E). (F) Quantified data show significantly lower calf muscle volume in Ab+vehicle-treated animals compared to Ab+EPO-treated group. * p,0.05.
doi:10.1371/journal.pone.0027067.g007
EPO and Nerve Repair
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e27067alone; however, this relationship did not reach statistical
significance due to small numbers of animals in each experimental
group. Our studies with anti-ganglioside Abs show that EPO can
overcome inhibition induced by these Abs in sciatic nerve injury
model. These animal findings suggest that EPO has proregenera-
tive effects that can overcome immune inhibitory signaling.
However, these neurotrophic effects are not specific to immune
injury and EPO could enhance nerve repair in other neuropathic
conditions. This is corroborated by other studies showing that
EPO is neuroprotective in metabolic and toxic models of
neuropathy [25,26,54]. The ability of EPO to promote axon
regeneration/nerve repair remains under-exploited [24] and our
studies add to the existing data on proregenerative effects of EPO
on neurite/axon growth in the peripheral nervous system. These
data support the possibility that EPO or its non-erythropoietic
forms/analogs [33,34,55] could be useful drugs for enhancing
nerve repair in immune and non-immune neuropathic conditions.
Clinical implications
GBS remains a major public health burden because a significant
proportion of patients require mechanical ventilation and 20%
have severe and permanent neurologic sequelae, including 10%
who cannot walk unaided [3,56,57]. Patients with residual deficits
and significant disability almost always have axonal injury and
target denervation [43]; recovery thus requires regeneration from
the site of axonal transection. Neuroprotective agents that can
limit the amount of nerve injury during the disease phase and
promote the nerve repair/axon regeneration during the recovery
phase of GBS are extremely desirable because they can limit the
permanent neurologic sequelae in patients with GBS.
In contrast to chronic neurological disorders, neuroprotective
and neurotrophic strategies are more likely to yield benefit in GBS
for the following reasons: a) the aberrant autoimmune responses
causing nerve injury are self-limited in GBS; b) peripheral nerves
have an inherent ability to regenerate and repair themselves after
injury; c) there is breakdown of blood-nerve barrier in injured
nerves, and neuroprotective drugs administered during the acute
phase of the disease are likely to reach the injured nerve fibres; and
d) neuroprotective and neurotrophic intervention(s) will be for a
limited period (because of the monophasic nature of GBS) and
thus less likely to lead to untoward side-effects that can potentially
appear with long term use of such drugs. EPO is a viable candidate
because of extensive clinical experience with its use in the
treatment of hematologic/anemic disorders [58] and substantial
preclinical and emerging clinical experience with its use for the
treatment of neurological disease models/disorders [33]. The two
potential limiting side-effect of chronic use of EPO for neuropro-
tection are increased risk of thromboembolism and its proproli-
ferative effects on preexisting neoplasia [59]. These side effects are
less likely to be a major issue in GBS because it is anticipated that
in this condition use of EPO or other proregenerative agents
would only be necessary for a limited/finite period to enhance
nerve repair, and patients with preexisting cancer can be excluded
from receiving this treatment. An alternate strategy would be to
consider non-erythropoietic forms of EPO, which retain their
neuroprotective properties but lack proproliferative effects on
myeloid tissues and are projected not to induce thromboembolism
[55].
In summary, now there is evidence that specific anti-ganglioside
Abs can injure intact nerve fibers [60–62] and also impair axon
regeneration via activation of specific signaling pathways that
inhibit regeneration [15–17]. The current therapies clearly
modulate the humoral and cellular immunity. Taken into account
the proregenerative effects of EPO in the cell culture and animal
models, underlines our concept, that addition of neurotrophic
therapies such as EPO, has the potential to enhance nerve repair
in patients with GBS.
Materials and Methods
Ethics Statement
All animals were handled according to protocols that were
approved by the Animal Welfare Committee at The University of
Texas Health Science Center at Houston (Protocol number: HSC-
AWC-08-071 and HSC-AWC-08-062) and that are in accordance
with Federal guidelines.
Anti-ganglioside monoclonal antibody
GD1a/GT1b–2b, a prototypic anti-ganglioside mAb well
characterized in cell culture and animal models [15,17,62–64],
was used in these studies. We have demonstrated that this mAb
severely inhibit axon regeneration in the sciatic nerve crush model
[15] and neurite outgrowth in primary neuronal cultures [17]. The
generation, specificity, production, and purification of this mAb
were reported previously [63]. The hollow fiber supernatant
containing GD1a/GT1b–2b (,3 mg/ml) was used in all animal
studies; purified GD1a/GT1b-2b was used in all cell culture
studies.
GBS and control sera
Seven GBS sera with high titers of IgG anti-GD1a and/or GM1
Abs, collected from patients with AMAN during the acute phase of
the disease, and five control sera collected from normal healthy
controls without ganglioside reactivity were used to study their
effects on primary rat DRG neurons. The IgG fractions from sera
were prepared with Protein G Sepharose column (GE healthcare,
Piscataway, NJ, USA) according to manufacturer’s instructions.
After purification the anti-ganglioside reactivities of IgG fractions
were reconfirmed with ELISA, as described [17].The studies with
GBS sera were restricted to neuronal cultures because large
quantities of sera are necessary to conduct animal studies.
Primary DRG neurons culture
Our previous study showed that anti-ganglioside Abs can inhibit
the neurite out-growth of neurons in the dissociated neuronal cell
cultures from embryonic (E15), postnatal (P5–8) rat DRG, and
adult mouse DRG [17]. EPO’s effect in reversing the anti-
ganglioside Abs mediated inhibition was therefore tested in those
primary DRG neuronal cultures, which were prepared as
described [17,65]. For the rat DRG cultures (embryonic and
postnatal DRGs), the dissociated neurons were plated on Poly-D-
Lysine (50 mg/ml; Sigma-Aldrich, St. Louis, MO)-coated glass
coverslips at low densities (5,000 cells/well) in 24-well plates
(Becton Dickinson, Franklin Lakes, NJ), and maintained in
neurobasal medium (Invitrogen, Carlsbad, CA) containing
0.25% (v/v) heat-inactivated Fetal Bovine Serum (FBS) (Hyclone,
Logan, UT), 2 mM L-glutamine, 2% B27-serumfree supplement
(Invitrogen), and 50 ng/ml of nerve growth factor (Sigma-
Aldrich). The DRG cultures from adult mouse were maintained
in F12 culture medium (Invitrogen) containing 10% FBS plus 1%
penicillin/streptomycin (Invitrogen), and the neurons were placed
onto Poly-D-Lysine coated coverslips at 10,000 cells per well.
Primary motor neuron enriched cultures
Spinal motor neurons cultures were prepared as described
[17,66] with minor modifications. E15 Sprague-Dawley rat spinal
cord were harvested and cleared of pia-arachnoid, grey matter was
harvested and cut into small pieces; this chopped tissue was
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terminated (L15+40%FBS) and followed by gentle trituration with
Pasteur pipette and differential centrifugation. The non-neuronal
glial cells only account for less than 20% of the total cell
population in this motor neuron enriched culture. The dissociated
cells were then plated on collagen coated glass cover slips into 24
well plates (5,000 cells/well) overnight. The growth medium
contains neurobasal medium supplemented with various additives
(which were all from Sigma-Aldrich unless otherwise stated)
including 2% B27 supplement (Invitrogen), 2.5 mg/ml albumin,
2.5 mg/ml catalase, 0.01 mg/ml transferrin, 15 mg/ml galactose,
6.3 ng/ml progesterone, 16 mg/ml putrescine, 4 ng/ml selenium,
and 1X penicillin/streptomycin. These mixed dissociated cultures
were stained with SMI-32 Abs (Sternberger Monoclonals,
Lutherville, MD) and used for studies described below.
Cell culture treatment with anti-ganglioside Abs and EPO
For all experiments GD1a/GT1b–2b (50–100 mg/ml) or
control IgG2b mAb (Abcam, Cambridge, MA), GBS or control
IgG fractions (100–500 mg/ml) were added 30 min after plating
the cells. Cell cultures were treated with either recombinant
human EPO (0.1–100 pM; EMD Chemicals, Gibbstown, NJ) or
vehicle (1X PBS; equal volume). After overnight incubation, cells
were fixed with 4% paraformaldehyde, stained with mAbs against
beta-III tubulin (1:5000; Promega, Madison, WI) or SMI-32 Abs,
and developed with specific secondary Abs conjugated to
fluorophores (1:200; Molecular Probes, Eugene, OR). Images
were acquired from randomly selected fields (n=8–12) at low
magnifications with a fluorescent upright microscope (Zeiss) by
using 20x lens; the longest neurite of each neuron was measured
and 80–120 neurons were included per condition. Neurite
outgrowth was quantified with IMAGE J, a public domain
image-processing program (http://rsb.info.nih.gov/ij/) or Axiovi-
sion (Zeiss), as described [17]. Each experimental condition was
done in duplicate wells and repeated at least 3 times with neurons
from a different set of animals. Neurite length for each condition
was normalized to the control and expressed as relative neurite
outgrowth. Controls included isotype-matched sham Abs, as
described [17].
Determination of EPOR and JAK2 activation in EPO-
mediated neurite elongation
These studies were performed to examine whether EPOR and
its downstream effectors are involved in overcoming anti-gnaglio-
side Ab-mediated inhibition of neurite outgrowth. DRG neuron
cultures were performed and neurite outgrowth was assessed, as
described above. Anti-EPOR blocking antibody (5 mg/ml; Santa
Cruz Biotechnology, Santa Cruz, CA) [34], or AG490 (JAK2
inhibitor, 1–25 mM; EMD Chemicals) were added to the cell
cultures 1 hour prior to treatment with EPO (100 pM for 24 h). A
subset of EPO treated cultures were co-incubated with soluble
EPOR (10 mg/ml; R&D Systems, Minneapolis, MN) to show that
exogenous EPOR can compete with endogenous EPOR. For
western blotting studies DRG cultures were treated with or
without 100 pM EPO for 10 min. Cells were harvested, sonicated,
and centrifuged. Protein quantification was performed on
supernatants, protein (30 mg of total protein/lane) electropho-
resed, and immunoblotting was performed with anti-phosphotyr-
osine (1:2,000; Millipore, Temecula, CA) and anti-phospho-
STAT5 (1:500; Millipore), as described [34,67]. Preliminary tests
were conducted to determine and optimize the concentration of
different reagents, including anti-EPOR antibody and soluble
EPOR (data not shown).
Determination of RhoA, Rac1 and Cdc42 activation after
EPO treatment
These studies were performed to examine whether EPO
modulates the activity of small GTPases RhoA, Rac1, and
Cdc42 in DRG neuron cultures. DRG cultures were serum
starved, EPO (10–1000 pM) was added to the cultures in the
presence of control or anti-ganglioside mAbs (10 mg/ml) and
control or patient derived IgG fractions (100–300 mg/ml) for
various intervals (0–30 min). Cells were then lysed and activity for
GTP-bound activated fraction of these GTPases (RhoA, Rac1 and
Cdc42) was determined by ELISA [17].
Sciatic nerve crush model
8 to 12-week-old wild-type (C57BL/6) were used in this study
for sciatic nerve crush model, as described [15]. All animals
underwent surgery, i.e., left sciatic nerve was crushed 35 mm
above the middle toe for 30 s with a fine forceps on day 0, as
described [15]. Age and gender matched animals were evenly
distributed into following 4 treatment groups: 1) GD1a/GT1b–2b
Ab + EPO; 2) GD1a/GT1b–2b Ab + vehicle; 3) Control Ab +
EPO; and 4) Control Ab + vehicle. Mice were administrated a
single dose of GD1a/GT1b–2b mAb (n=18; 750ul of hollow fiber
supernatant containing ,2 mg of Ab) or control Abs (n=18; 2 mg
of purified mouse IgG) on day 3 after the nerve crush by
intraperitoneal route. EPO (42 mg/kg) or vehicle control was
administered subcutaneously to animals 5 days/week for 30 days
after the nerve crush. The electrophysiology studies were done on
days 16, 26, and 30 after the nerve crush. Studies were terminated
on day 30 after the crush and nerve tissues and sera were
harvested for morphological and serological analysis from all
animals. Serological studies for GD1a and GT1b ganglioside
binding were done by ELISA, as described [15].
Morphometry
All animals were perfused and sciatic and tibial nerves were
harvested and post-fixed in 4% paraformaldehyde overnight
before processing. Sciatic nerve segments (n=36; ,10 mm distal
to the crush site and tibial nerve segments (n=36; ,20 mm distal
to the crush site) were embedded in Epon. One mm cross sections
were stained with toluidine blue, as described [15,68]. For
quantification, all myelinated axons in a single whole cross section
of the nerve were counted at light level (40X) by using a motorized
stage and stereotactic imaging software (Axiovision; Zeiss, Thorn-
wood, NY). Selected nerves (n=6) were also examined by electron
microscopy.
Electrophysiology
Sciatic nerve conduction studies were performed on all animals.
CMAP amplitudes were recorded in the hindpaw on day 16, 26,
and 30 after nerve crush, as described [15].
Ex-vivo Magnetic resonance imaging
A subset of animals were perfused (n=6), and post-fixed in 4%
paraformaldehyde for 24 hours at 4uC. Ex vivo T2-weighted
magnetic resonance images of the calf region (between knee and
ankle) were acquired on a vertical 11.7T NMR spectrometer
(Bruker Biospec, Billerica, MA, USA) and processed, as described
[40]. From 3D images of the leg, volumetric measurements of all
muscle groups were obtained. We have previously validated this
MRI measure and it reflects denervation and reinnervation
associated changes in calf muscle and fiber size within the 4 week
time period (also used in this study) in sciatic nerve injury models
[15,16,40].
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All numerical results are presented as mean + SEM. Differences
between groups were determined using ANOVA with corrections
for multiple comparisons or student’s t test, p values ,0.05 were
considered statistically significant.
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